Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > July 4, 2022
Daily News
July 4, 2022
- INES Launches Study Group to Propose Stable Healthcare Financing
July 4, 2022
- 8 VC Firms Certified for AMED Funding Project to Boost Pharma Ecosystem
July 4, 2022
- Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
July 4, 2022
- 5 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 4, 2022
- Online NDA Submission Starts in Japan: MHLW/PMDA
July 4, 2022
- VLP and Shionogi 1st to Be Selected for SCARDA Vaccine Funding Program
July 4, 2022
- UCB Japan Snaps Up Zogenix Japan, Employees Too
July 4, 2022
- AstraZeneca Japan Taps Ex-Takeda Japan Oncology Head as New Chief
July 4, 2022
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…